



# Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally

Tiziana Masini<sup>1</sup>, Avinash Kanchar<sup>1</sup>, Fuad Mirzayev<sup>1</sup>, Kerri Viney<sup>1</sup>, Askar Yedilbayev<sup>2</sup>, Matteo Zignol<sup>1</sup> and Dennis Falzon<sup>1</sup>

<sup>1</sup>Global Tuberculosis Programme, World Health Organization, Geneva, Switzerland. <sup>2</sup>World Health Organization, Regional Office for Europe, Copenhagen, Denmark.

Corresponding author: Tiziana Masini (tmasini@who.int)



Shareable abstract (@ERSpublications)

**Global access to rifapentine is essential to implement the latest WHO recommendations on treatment of TB infection and disease. Measures to increase access to rifapentine include strengthening regulatory reliance practices.** <https://bit.ly/3xNDwID>

**Cite this article as:** Masini T, Kanchar A, Mirzayev F, *et al.* Wider access to quality-assured rifapentine-based regimens is needed to accelerate tuberculosis prevention and care globally. *Eur Respir J* 2022; 60: 2201227 [DOI: 10.1183/13993003.01227-2022].

This single-page version can be shared freely online.

Copyright ©The authors 2022.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 15 June 2022  
Accepted: 19 June 2022

*To the Editor:*

In their correspondence, GUGLIELMETTI *et al.* [1] emphasise the importance of improved access to rifapentine globally, both for the treatment of tuberculosis (TB) disease and as part of TB preventive treatment (TPT) regimens. They also highlight some of the major problems with access to this medicine, especially in the European Union (EU), foremost amongst which being the absence of market authorisation of rifapentine in the EU. In this letter we highlight key actions taken by the World Health Organization (WHO) to address important barriers to the implementation of recommendations on rifapentine.

